Flyer
GLP-1 Platform
The rapidly expanding GLP-1 market—projected to reach $157.5 billion by 2035—demands agile, expert partners. BioDuro delivers comprehensive capabilities to drive your metabolic disease programs forward.
Key Highlights
- Integrated Platform: From discovery to development with biology, peptide synthesis, and ADME/PK services
- Proven Expertise: Successfully delivered Semaglutide analogues and 10,000+ peptides annually
- Rapid Turnaround: Achieve 3-week peptide synthesis and 5-day study results
- Disease Models: Validated models for diabetes, obesity and NASH/MASH research
Download the full flyer to explore our complete GLP-1 capabilities.
Fill in your data to download the flyer
